Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
A fatal mycotic sepsis after retrograde intrarenal surgery: a case report and literature review.
Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor.
Chronic pain disrupts the reward circuitry in multiple sclerosis.
Scientists probe strategies to repair neuron damage in multiple sclerosis.
Patterns of Use of Tests to Monitor Disease Activity Among Patients With Relapsing Remitting Multiple Sclerosis in the United States and Europe.
Japanese macaque encephalomyelitis: a spontaneous multiple sclerosis-like disease in a nonhuman primate.
All relapsing multiple sclerosis patients should be seen in specialist clinics - NO.
Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.
Pharmacoeconomic Aspects of Multiple Sclerosis Treatments in Iran.
Factors Associated with Caregiver's Burden in Relapsing-Remitting Multiple Sclerosis and Satisfaction with Current Therapies. MS-Feeling Study.
Consent guidance: patients and doctors making decisions together
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Efficacy of hematopoietic stem cell formultiple sclerosis, an evidence based meta-analysis.
CellCept (Product Insert)
A review of Neuropharmacology Effects of Nigella sativa and Its Main Component, Thymoquinone.
Co-occurrence of multiple sclerosis and Parkinson disease.
25 Hydroxyvitamin D and Cytokines in Multiple Sclerosis.
Multiple sclerosis: Bigger brains resist disability in MS.
Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy.
Defining the clinical course of multiple sclerosis: The 2013 revisions.
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
A Study of Efficacy and Safety of Ocrelizumab in Patients with Relapse-Remitting Multiple Sclerosis
The complex role of estrogens in inflammation.
Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55.
Histologie de la sclerose en plaques